Skip to main content
Premium Trial:

Request an Annual Quote

Chip Maker, Aclara to Make $97 Million Offering

Premium

M

OUNTAIN VIEW, Calif.--Aclara Biosciences, which makes chips for genetic analysis, drug screening, and other uses, filed to raise more than $97 million in an initial public offering, said a Reuters report. Details such as the number of shares and the expected price range of them were not included in the filing to the Securities and Exchange Commission.

Net proceeds from the offering will be applied to R&D, possible acquisitions, and investments in its technology as well as for working capital and other general corporate purposes, reported Reuters. The company makes its "lab-on-a-chip" products to enable researchers to rapidly perform large numbers of chemical and biological measurements in a miniaturized, automated format.

Filed under

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.